Author: cpereira@noblefcm.com

E.W. Scripps (SSP) – Takes Steps To Assuage Debt Concerns

Posted on by cpereira@noblefcm.com


Wednesday, March 12, 2025

The E.W. Scripps Company (NASDAQ: SSP) is a diversified media company focused on creating a better-informed world. As one of the nation’s largest local TV broadcasters, Scripps serves communities with quality, objective local journalism and operates a portfolio of 61 stations in 41 markets. The Scripps Networks reach nearly every American through the national news outlets Court TV and Newsy and popular entertainment brands ION, Bounce, Defy TV, Grit, ION Mystery, Laff and TrueReal. Scripps is the nation’s largest holder of broadcast spectrum. Scripps runs an award-winning investigative reporting newsroom in Washington, D.C., and is the longtime steward of the Scripps National Spelling Bee. Founded in 1878, Scripps has held for decades to the motto, “Give light and the people will find their own way.”

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q4 results exceed expectations. Revenues increased a strong 18.3% to $728.4 million, beating our $716.1 million estimate. The results benefited from better core advertising ($147.4 million vs our $143.0 million est.) and higher Political revenue ($174.4 million vs our $172.0 million est.). Adj. EBITDA was $229.6 million, better than our $226.1 million estimate. Figure #1 Q4 Results highlight our estimates versus reported results. 

Sluggish start. Management provided lackluster Q1 revenue guidance, expecting Local Media revenue to be down high single- digits with Scripps Networks revenue to be down mid single-digits. The sluggish Q1 reflects the absence of Political revenue, but likely weak core spot and National spot advertising. Notably, management guided interest expense to be $175 million to $185 million, less than our estimate of roughly $200 million. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Commercial Vehicle Group (CVGI) – Tough End to a Challenging Year

Posted on by cpereira@noblefcm.com


Wednesday, March 12, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

4Q Results. CVG reported 4Q24 revenue of $163.3 million, down 15.7% y-o-y due to ongoing weakness in the Construction and Ag markets, as well as a drop in Class 8 truck builds. Adjusted EBITDA was $0.9 million, down from $8.3 million. CVG reported an adjusted loss from continuing operations of $5.1 million, or a loss of $0.15/sh, compared to adjusted net income of $2.1 million, or EPS of $0.06, in 4Q23.

Strategic Initiatives. The Company implemented a number of strategic initiatives during 2024, including portfolio rationalization and the elimination of some 1,300 positions. These should result in some $15 million of gross savings in 2025, which should help improve margins.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Zomedica Corp. (ZOM) – Fundamentals Have Been Improving, But Price Weakness Leads To Delisting

Posted on by cpereira@noblefcm.com


Tuesday, March 11, 2025

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Recent Price Weakness Forces Move To The OTC Bulletin Board. As the recent decline in the overall markets was affecting companies in many sectors, the closing price of Zomedica stock fell below $0.10 per share on March 3. This crossed a threshold set by the New York American exchange, forcing the delisting of ZOM shares. Zomedica shares began trading on the OTCQB Venture Market under the symbol ZOMDF. There were no other events or crisis that caused the delisting.

During 2024, Zomedica Has Met All Of The Product Goals We Expected. Over the past year, Zomedica has introduced several new assays for use with its TRUFORMA diagnostics platform. These assays are sold to veterinary practices for use with TRUFORMA diagnostic instruments, allowing the veterinarian to run tests without sending samples to an outside lab. This allows the diagnosis in a few minutes and allows the practice to capture the profit from the tests. The TRUFORMA assays, reported as diagnostic consumables, have been one of the sources of sales growth over the past year.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Gyre Therapeutics, Inc (GYRE) – Initiation of Coverage: Focused On Fibrosis

Posted on by cpereira@noblefcm.com


Tuesday, March 11, 2025

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

We Are Initiating Coverage Of Gyre Therapeutics With An Outperform Rating. Gyre Therapeutics is a pharmaceutical company developing drugs for inflammatory diseases that lead to fibrosis. It currently markets Etuary (pirfenidone) in China for idiopathic pulmonary fibrosis. The lead drug in the pipeline is Hydronidone, a new molecule derived from pirfenidone, that is in a Phase 3 clinical trial in China. The data announcement is expected to report Phase 3 clinical trial results in March 2025.

Hydronidone Was Developed To Improve Efficacy and Side Effects. Hydronidone is a structural analogue of pirfenidone that was developed to improve efficacy with a more tolerable side effect profile. It is in Phase 3 trial in China for fibrosis of the liver after hepatitis B (HBV) infections. Hydronidone targets steps in the Transforming Growth Factor (TGF)-ß1 pathway as well as the downstream genes and liver cells it activates to produce fibrotic tissue. Data from the Phase 3 in China will be used to design a Phase 2a trial in the US, expected to begin in late FY2025.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

AZZ Inc. (AZZ) – Updating Estimates to Reflect AVAIL Transaction

Posted on by cpereira@noblefcm.com


Tuesday, March 11, 2025

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

AVAIL joint venture. Through a joint venture, AZZ owns a non-controlling 40% interest in Avail Infrastructure Solutions with the remaining 60% owned by the Fernweh Group LLC. Avail recently executed a definitive agreement to sell its Electrical Products Group to nVent Electric plc (NYSE: NVT) for $975 million, subject to adjustments. The transaction is expected to close during the first half of the 2025 calendar year. AZZ will continue to own a 40% interest in Avail which will consist of its Industrial Lighting and Welding Solutions businesses.

Use of proceeds. AZZ will use its share of the transaction proceeds to further reduce debt or fund potential M&A activity. The gain on the transaction will be treated as a one-time adjustment to net income and EPS. A reduction in the $16 million to $18 million of joint venture equity income included in AZZ’s fiscal year 2026 guidance is expected to be offset by interest savings. While AZZ is not adjusting its fiscal year 2026 earnings guidance, debt reduction will be higher than the range of $140 million to $160 million provided in their guidance.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

The ODP Corporation (ODP) – New Partnership

Posted on by cpereira@noblefcm.com


Monday, March 10, 2025

Office Depot, Inc., together with its subsidiaries, supplies a range of office products and services. It offers merchandise, such as general office supplies, computer supplies, business machines and related supplies, and office furniture through its chain of office supply stores under the Office Depot, Foray, Ativa, Break Escapes, Worklife, and Christopher Lowell brand names. The company also provides graphic design, printing, reproduction, mailing, shipping, and other services through design, print, and ship centers. It has operations throughout North America, Europe, Asia, and Central America. The company also sells its products and services through direct mail catalogs, contract sales force, Internet sites, and retail stores, through a mix of company-owned operations, joint ventures, licensing and franchise agreements, alliances, and other arrangements. As of December 31, 2008, Office Depot operated 1,267 North American retail division office supply stores and 162 international division retail stores, as well as participated under licensing and merchandise arrangements in 98 stores. The company was founded in 1986 and is based in Boca Raton, Florida.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New Partnership. The ODP Corporation continued its B2B push with the signing of a new partnership agreement with CoreTrust. The agreement marks the latest in a series of new contracts for ODP Business Solutions, moving the segment into new, growing industries. Through this partnership, ODP Business Solutions will offer products and services to CoreTrust’s 3,500+ business member purchasing collective, which serves major industries including retail, manufacturing, hospitality, and finance.

Details. Under the contract, ODP Business Solutions will supply CoreTrust members with high-quality solutions, including interiors/furniture, technology, breakroom supplies, and paint, promotion, and apparel services at an exceptional value. These categories are expected to expand industry wide by a 4-6% compound annual growth rate over the next five years.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Information Services Group (III) – Noticing Positive Trends in 2025

Posted on by cpereira@noblefcm.com


Monday, March 10, 2025

ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 700 clients, including more than 75 of the world’s top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,300 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For additional information, visit www.ISG-One.com

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Improved Metrics. While fourth quarter revenue was down on a reported basis, it was in-line with our expectations and at the upper-end of management’s $57-$58 million guidance. Importantly, ISG delivered an improved gross margin of 41.5% from 38.3% last year due to higher utilization and the sale of its automation unit. Flowing through to the bottom line, adjusted EBITDA had an improved margin of 11.3% from 8.9% last year.

A Year of Headwinds. Fiscal year 2024 was highlighted by headwinds for the Company, as its clients delayed decision making throughout the year. Uncertainty regarding the macroenvironment, geopolitical conflict in Europe, and political uncertainty impacted spending in 2024.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Direct Digital Holdings (DRCT) – Diversifying Revenue Sources

Posted on by cpereira@noblefcm.com


Monday, March 10, 2025

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Focus on rebuilding revenue. Over the past several months, the company has been focused on diversifying its revenue streams as it rebuilds revenue. Prior to Q3, the company’s largest sell-side customer accounted for roughly 80% of the segment’s revenue. After the large client reduced volume, negatively impacting Q3 results, the company is focused on not letting any one client comprise more than 20% – 30% of revenue.

New joint venture. On March 5, the company announced a new joint venture, Teranexa, with Green Tea Technology. This venture is focused on utilizing AI to improve efficiencies in small and medium-sized cities. Notably, Teranexa will combine the company’s data monetization expertise with Green Tea’s experience in IT project deployment, leveraging its partner network of IBM and HPE.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Comstock Inc. (LODE) – Full Year 2024 Review and Outlook

Posted on by cpereira@noblefcm.com


Monday, March 10, 2025

Comstock (NYSE: LODE) innovates technologies that contribute to global decarbonization and circularity by efficiently converting under-utilized natural resources into renewable fuels and electrification products that contribute to balancing global uses and emissions of carbon. The Company intends to achieve exponential growth and extraordinary financial, natural, and social gains by building, owning, and operating a fleet of advanced carbon neutral extraction and refining facilities, by selling an array of complimentary process solutions and related services, and by licensing selected technologies to qualified strategic partners. To learn more, please visit www.comstock.inc.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Investor webinar. On March 6, Comstock hosted a webinar to discuss the company’s full year 2024 results and provided a comprehensive business update. Management highlighted significant accomplishments achieved in 2024 and its plans for 2025.

Upcoming events. While Comstock summarized corporate and subsidiary-level objectives for 2025, we view several as significant. These include: 1) Comstock Fuels’ completion of offtake, joint development, and warrant agreements with Marathon Petroleum Corporation on or before June 30, 2025, 2) completion of a Comstock Fuels Series A financing during the second quarter, 3) construction of Comstock Metals’ first large-scale recycling facility at a cost of $6 million, 4) advancement of project level financing for subsidiary projects, and 5) the sale of Comstock’s properties and water rights in Silver Springs, Nevada in the latter part of 2025.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Information Services Group (III) – A Peak into the Fourth Quarter

Posted on by cpereira@noblefcm.com


Friday, March 07, 2025

ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 700 clients, including more than 75 of the world’s top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,300 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For additional information, visit www.ISG-One.com

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Fourth Quarter Results. Revenue for the quarter totaled $57.8 million, nearing the top of management’s guidance and in-line with our estimate of $58 million. Net income totaled $3.0 million, or $0.06 per diluted share, an improvement from a loss of $2.9 million or $0.06 per share, last year. We estimated a net loss of $0.2 million or breakeven per share. Adjusted EBITDA was $6.5 million, the midpoint of management’s guidance and above our estimate of $6 million.

More Cash in Hand. ISG generated cash from operations of $6.6 million during the quarter, and with the sale of the automation unit last quarter, had total cash on hand of $23.1 million at the end of the quarter, up 138% from the prior quarter. Debt declined to 25% y-o-y to $59.2 million as of December 31, 2024. Management maintained a goal of 2.0-2.5x debt to EBITDA ratio.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

NN, Inc. (NNBR) – Transformation Taking Effect

Posted on by cpereira@noblefcm.com


Friday, March 07, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Remain on Track. The first full year of NN’s transformation produced significant results, although the improvements were somewhat obscured in the GAAP reported results. With the successful change in the business trajectory, NN remains on track to achieve its 2028 financial goals of $650 million of net sales, with an adjusted EBITDA margin in the 12-13% range.

More Transformation in 2025. Management is not resting on its laurels. 2025 will continue the transformation plan with specific emphasis on improving or eliminating underperforming business, additional costs out, new business wins, and balance sheet improvement through a debt refinance.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Seanergy Maritime Holdings (SHIP) – Record Profitability in 2024; Updating 2025 Estimates

Posted on by cpereira@noblefcm.com


Friday, March 07, 2025

Seanergy Maritime Holdings Corp. is a prominent pure-play Capesize shipping company listed in the U.S. capital markets. Seanergy provides marine dry bulk transportation services through a modern fleet of Capesize vessels. The Company’s operating fleet consists of 18 vessels (1 Newcastlemax and 17 Capesize) with an average age of approximately 13.4 years and an aggregate cargo carrying capacity of approximately 3,236,212 dwt. Upon completion of the delivery of the previously announced Capesize vessel acquisition, the Company’s operating fleet will consist of 19 vessels (1 Newcastlemax and 18 Capesize) with an aggregate cargo carrying capacity of approximately 3,417,608 dwt. The Company is incorporated in the Marshall Islands and has executive offices in Glyfada, Greece. The Company’s common shares trade on the Nasdaq Capital Market under the symbol “SHIP”.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Fourth quarter financial results. Seanergy Maritime reported fourth quarter adjusted EBITDA and earnings per share (EPS) of $20.4 million and $0.34, respectively, exceeding our estimates of $19.3 million and $0.27. Revenue was modestly above our estimate due to better-than-expected available operating days, while expenses were marginally lower-than-expected, driven by operational efficiencies for voyage and vessel expenses. Operating income was $10.7 million compared to our estimate of $10.1 million.

2025 market outlook. Capesize rates fell in early 2025 due to an increase in the effective supply of vessels caused by low congestion in ports and smaller vessels taking on cargo typically reserved for the Capesize fleet. However, Capesize market rates have since rebounded and are expected to stay relatively steady throughout 2025. Limited new vessel orders and deliveries, increasing environmental regulations, and rising iron ore and bauxite exports are supporting Cape vessel rates amid a broader downturn in the dry-bulk market.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Ocugen (OCGN) – Ocugen Reports FY2024 With Progress Toward “3 BLA Filings In 3 Years”

Posted on by cpereira@noblefcm.com


Thursday, March 06, 2025

Ocugen, Inc. is a biotechnology company focused on developing and commercializing novel gene therapies, biologicals, and vaccines. The lead product in its gene therapy program, OCU400, is in Phase 1/2 clinical trials for retinitis pigmentosa.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Clinical Progress Expected To Lead To Filings For Three Product Approvals. Ocugen reported a 4Q24 loss of $13.9 million or $(0.05) per share and FY2024 loss of $54.1 million or $(0.20) per share. The company made significant progress in its clinical trials during the quarter and since the start of FY2025. It has also received regulatory designations that accelerate product approval. The company had $58.5 million in cash on December 31, sufficient to fund operations through 1Q26.

Clinical Trial Advances Point To Three BLAs In 3 Years. Ocugen has made significant progress with three products for three diseases that lead to vision loss. The three ongoing trials are Phase 3 for OCU400, the Phase 2/3 for OCU410ST in Stargardt disease, and the Phase 1/2 trial for GA. These trials are on schedule for filing applications for approval in 2026, 2027, and 2028 respectively. OCU400 and OCU410ST have Orphan Drug designations that can accelerate approval, while GA is a large market of over 10 million patients in the US alone.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.